Cancer Genetics (NASDAQ:CGIX) Receives New Coverage from Analysts at

Research analysts at assumed coverage on shares of Cancer Genetics (NASDAQ:CGIXGet Rating) in a report issued on Sunday. The firm set a “sell” rating on the stock.

Cancer Genetics Stock Up 4.7 %

NASDAQ:CGIX opened at $1.56 on Friday. Cancer Genetics has a twelve month low of $2.11 and a twelve month high of $17.50. The stock’s 50 day moving average price is $0.69 and its two-hundred day moving average price is $0.76.

Cancer Genetics Company Profile

(Get Rating)

Vyant Bio, Inc is emerging as an advanced biotechnology drug discovery company. The firm is focused on human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners, as well as for its proprietary pipeline. The company with capabilities in data, science (both biology and chemistry), engineering, and regulatory, it rapidly identifying small and large molecule therapeutics and derisking decision making through multiple in silico, in vitro, and in vivo modalities.

Recommended Stories

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with's FREE daily email newsletter.